|
1
|
De Felice F, Polimeni A, Valentini V,
Brugnoletti O, Cassoni A, Greco A, De Vincentiis M and Tombolini V:
Radiotherapy controversies and prospective in head and neck cancer:
A literature-based critical review. Neoplasia. 20:227–232. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vermorken JB, Stöhlmacher-Williams J,
Davidenko I, Licitra L, Winquist E, Villanueva C, Foa P, Rottey S,
Skladowski K, Tahara M, et al: Cisplatin and fluorouracil with or
without panitumumab in patients with recurrent or metastatic
squamous-cell carcinoma of the head and neck (SPECTRUM): An
open-label phase 3 randomised trial. Lancet Oncol. 14:697–710.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vermorken JB, Licitra L,
Stöhlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hamid O,
Hossain AM, Chang SC and Gauler TC: Phase II study of pemetrexed in
combination with cisplatin and cetuximab in recurrent or metastatic
squamous cell carcinoma of the head and neck. Eur J Cancer.
49:2877–2883. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan
PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar
AK, et al: Randomized phase III trial of concurrent accelerated
radiation plus cisplatin with or without cetuximab for stage III to
IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 32:2940–2950.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martins RG, Parvathaneni U, Bauman JE,
Sharma AK, Raez LE, Papagikos MA, Yunus F, Kurland BF, Eaton KD,
Liao JJ, et al: Cisplatin and radiotherapy with or without
erlotinib in locally advanced squamous cell carcinoma of the head
and neck: A randomized phase II trial. J Clin Oncol. 31:1415–1421.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Numico G, Franco P, Cristofano A,
Migliaccio F, Spinazzé S, Silvestris N, Cante D, Sciacero P, La
Porta MR, Girelli F and Ricardi U: Is the combination of Cetuximab
with chemo-radiotherapy regimens worthwhile in the treatment of
locally advanced head and neck cancer? A review of current
evidence. Crit Rev Oncol Hematol. 85:112–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
De Santis R, Albertoni C, Rosi A, Leoni B,
Petronzelli F, D'Alessio V, Nucera E, Salvatori G, Paganelli G,
Verdoliva A, et al: OXavidin for tissue targeting biotinylated
therapeutics. J Biomed Biotechnol. 2009:9214342009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
De Santis R, Leoni B, Rosi A, Albertoni C,
Forni G, Cojoca R, Iezzi M, Musiani P, Paganelli G, Chinol M and
Carminati P: AvidinOX for highly efficient tissue-pretargeted
radionuclide therapy. Cancer Biother Radiopharm. 25:143–148. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Santis R, Anastasi AM, Pelliccia A,
Rosi A, Albertoni C, Verdoliva A, Petronzelli F, D'Alessio V,
Serani S and Nuzzolo CA: Chemical linkage to injected tissues is a
distinctive property of oxidized avidin. PLoS One. 6:e210752011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nucera E, Nicoletti C, Chiapparino C,
Pacello ML, D'Alessio V, Musarò A and De Santis R: AvidinOX™ for
tissue targeted delivery of biotinylated cells. Int J Immunopathol
Pharmacol. 25:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Verdoliva A, Bellofiore P, Rivieccio V,
Catello S, Colombo M, Albertoni C, Rosi A, Leoni B, Anastasi AM and
De Santis R: Biochemical and biological characterization of a new
oxidized avidin with enhanced tissue binding properties. J Biol
Chem. 285:9090–9099. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Albertoni C, Leoni B, Rosi A, D'Alessio V,
Carollo V, Spagnoli LG, van Echteld C and De Santis R: Radionuclide
therapy of unresectable tumors with AvidinOX and (90) Y-biotinDOTA:
Tongue cancer paradigm. Cancer Biother Radiopharm. 30:291–298.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vesci L, Milazzo FM, Anastasi AM,
Petronzelli F, Chiapparino C, Carollo V, Roscilli G, Marra E,
Luberto L, Aurisicchio L, et al: Intra-tumor AvidinOX allows
efficacy of low dose systemic biotinylated Cetuximab in a model of
head and neck cancer. Oncotarget. 7:914–928. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Urbano N, Papi S, Ginanneschi M, De Santis
R, Pace S, Lindstedt R, Ferrari L, Choi S, Paganelli G and Chinol
M: Evaluation of a new biotin-DOTA conjugate for pretargeted
antibody-guided radioimmunotherapy (PAGRIT). Eur J Nucl Med Mol
Imaging. 34:68–77. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kilkenny C, Browne WJ, Cuthill JC, Emerson
M and Altman DG: Improving bioscence research reporting: The ARRIVE
guidelines for reporting animal research. Osteoarthritis Cartilage.
20:256–260. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Massi D, Puig S, Franchi A, Malvehy J,
Vidal-Sicart S, González-Cao M, Baroni G, Ketabchi S, Palou J and
Santucci M: Tumour lymphangiogenesis is a possible predictor of
sentinel lymph node status in cutaneous melanoma: A case-control
study. J Clin Pathol. 59:166–173. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schneider CA, Rasband WS and Eliceiri KW:
NIH image to imageJ: 25 years of image analysis. Nat Methods.
9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Romanelli S, Perego P, Pratesi G, Carenini
N, Tortoreto M and Zunino F: In vitro and in vivo interaction
between cisplatin and topotecan in ovarian carcinoma systems.
Cancer Chemother Pharmacol. 41:385–390. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
De Santis R, Rosi A, Anastasi AM,
Chiapparino C, Albertoni C, Leoni B, Pelliccia A, Santapaola D,
Carollo V, Marra E, et al: Efficacy of aerosol therapy of lung
cancer correlates with EGFR paralysis induced by AvidinOX-anchored
biotinylated Cetuximab. Oncotarget. 5:9239–9255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Milazzo FM, Anastasi AM, Chiapparino C,
Rosi A, Leoni B, Vesci L, Petronzelli F and De Santis R:
AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce
down-modulation of ErbB2 and tumor cell death at concentrations
order of magnitude lower than not-anchored antibodies. Oncotarget.
8:22590–22605. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Basu A and Krishnamurthy S: Cellular
responses to cisplatin-induced DNA damage. J Nucleic Acids.
2010(pii): 2013672010.PubMed/NCBI
|
|
23
|
Arimoto S, Hasegawa T, Takeda D, Saito I,
Amano R, Akashi M and Komori T: Lymphangiogenesis and lymph node
metastasis in oral squamous cell carcinoma. Anticancer Res.
38:6157–6162. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lonser RR, Sarntinoranont M, Morrison PF
and Oldfield EH: Convection-enhanced delivery to the central
nervous system. J Neurosurg. 122:697–706. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Beitler JJ, Zhang Q, Fu KK, Trotti A,
Spencer SA, Jones CU, Garden AS, Shenouda G, Harris J and Ang KK:
Final results of local-regional control and late toxicity of RTOG
9003: A randomized trial of altered fractionation radiation for
locally advanced head and neck cancer. Int J Radiat Oncol Biol
Phys. 89:13–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kfoury M, Disdero V, Vicier C, Le Saux O,
Gougis P, Sajous C and Vignot S: Immune checkpoints inhibitors:
Recent data from ASCO's meeting 2017 and perspectives. Bull Cancer.
105:686–695. 2018.(In French). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yoneda K, Imanishi N, Ichiki Y and Tanaka
F: Immune checkpoint inhibitors (ICIs) in non-small cell lung
cancer (NSCLC). J UOEH. 40:173–189. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Durante M and Formenti SC:
Radiation-induced chromosomal aberrations and immunotherapy:
Micronuclei, cytosolic DNA, and interferon-production pathway.
Front Oncol. 8:1922018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ni K, Lan G, Chan C, Quigley B, Lu K, Aung
T, Guo B, La Riviere P, Weichselbaum RR and Lin W: Nanoscale
metal-organic frameworks enhance radiotherapy to potentiate
checkpoint blockade immunotherapy. Nat Commun. 9:23512018.
View Article : Google Scholar : PubMed/NCBI
|
